Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, tumor types and companies are setting the path?

* How much R&D effort has gone towards different targets and what is known about the target?

* Indication expansion opportunities

* Drug repositioning opportunities

* Which pathways are targeted, by what and how?

* What is truly new and unique in the antibody pipeline in cancer?

* How new and unique your target strategy really is

* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 572 antibody drugs in cancer from within the portfolio of 205 companies world-wide, from Ceased to Marketed. We have identified 270 drug targets, which we have organized into 279 drug target strategies, and assessed them by four levels:

1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Indication: Shows the distribution and deployment of target strategies by cancer indications. The competitive level in each cancer indication is assessed.

4. Company: Provides a cross-examination of each company’s entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:

* Head-to-head target competing analysis

* Significant drug target overlap analysis

* Cross-sectional R&D profiling of individual drug targets.

* Cross-over analysis of target strategies among different tumor types.

* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company’s pipeline:
-Where are we?
-Where is our general and specific competition?
-What is the level of competition where we want to be?

* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company’s interest in the antibody pipeline in cancer by:

* Better identifying benchmarking peers

* Providing rationale for in/out licensing decisions of drug candidates

* Performing proper drug due diligence

* Strategies for commercial planning

* Guiding Research & Development efforts

Table Of Contents

1 Executive Summary 3
2 About Cancer Highlightsâ„¢ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 23
4.2 List of Tables 23
5 Introduction 35
5.1 The Scope of this Report 35
5.2 Definitions 38
5.3 Abbreviations 38
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment 39
6.1 Drug Repositioning in Oncology 39
6.2 Introduction to Targets of Antibody Drugs in Cancer 40
6.2.1 Antigen Binding Targets 49
6.2.2 ATPase Activity Targets 51
6.2.3 Auxiliary Transport Protein Activity Targets 53
6.2.4 B Cell Receptor Activity Targets 56
6.2.5 Binding Targets 57
6.2.6 Carboxypeptidase Activity Targets 58
6.2.7 Catalytic Activity Targets 60
6.2.8 Cell Adhesion Molecule Activity Targets 64
6.2.9 Chaperone Activity Targets 88
6.2.10 Chemokine Activity Targets 91
6.2.11 Cofactor Binding Targets 95
6.2.12 Complement Activity Targets 97
6.2.13 Cysteine-type Peptidase Activity Targets 101
6.2.14 Cytokine Activity Targets 103
6.2.15 Defense/Immunity Protein Activity Targets 110
6.2.16 DNA Topoisomerase Activity Targets 111
6.2.17 Extracellular Ligand-gated Ion Channel Activity Targets 114
6.2.18 Extracellular Matrix Structural Constituent Targets 115
6.2.19 G-protein Coupled Receptor Activity Targets 121
6.2.20 Growth Factor Activity Targets 134
6.2.21 Guanylate Cyclase Activity Targets 149
6.2.22 Hormone Activity Targets 150
6.2.23 Hydrolase Activity Targets 151
6.2.24 Intracellular Ligand-gated Ion Channel Activity Targets 153
6.2.25 Kinase Binding Targets 154
6.2.26 Metallopeptidase Activity Targets 155
6.2.27 MHC Class I Receptor Activity Targets 159
6.2.28 Molecular Function Unknown Targets 160
6.2.29 Oxidoreductase Activity Targets 189
6.2.30 Peptidase Activity Targets 190
6.2.31 Peptide Hormone Targets 192
6.2.32 Protease Inhibitor Activity Targets 194
6.2.33 Protein Binding Targets 196
6.2.34 Protein Serine/Threonine Kinase Activity Targets 197
6.2.35 Receptor Activity Targets 201
6.2.36 Receptor Binding Targets 269
6.2.37 Receptor Signaling Complex Scaffold Activity Targets 282
6.2.38 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 284
6.2.39 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 286
6.2.40 RNA-directed DNA Polymerase Activity Targets 287
6.2.41 Serine-type Peptidase Activity Targets 288
6.2.42 Structural Constituent of Cytoskeleton Targets 291
6.2.43 Structural Molecule Activity Targets 293
6.2.44 T Cell Receptor Activity Targets 294
6.2.45 Transcription Factor Activity Targets 296
6.2.46 Transcription Regulator Activity Targets 301
6.2.47 Translation Regulator Activity Targets 304
6.2.48 Transmembrane Receptor Activity Targets 305
6.2.49 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 314
6.2.50 Transporter Activity Targets 348
6.2.51 Other Targets 352
6.3 Mutation Profiles of Antibody Drug Targets in Oncology 356
6.3.1 Targets of Antibody Drugs in Cancer Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 356
6.4 Antibody Therapeutics is Stimulated by Available Structure Data on Targets 364
6.5 Target-Target Interactions among Identified Targets of Antibody Drugs in Cancer 368
6.6 Protein Expression Levels of Identified Targets of Antibody Drugs in Cancer 372
6.7 The Drug-Target Competitive Landscape 375
6.8 Pathway Assessment of Antibody Drugs in Cancer 381
6.8.1 Tools for Analysis of Cancer Pathways 382
6.8.2 Pathway Assessment 383
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development 423
7.1 Pre-registrered and Marketed: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 426
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 428
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 430
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 435
7.5 Preclinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 442
7.6 Drug Target Strategies of Suspended or Terminated Antibody Drugs in Cancer 451
7.7 Target Strategy Development Profiles of Antibody Drugs in Cancer 456
7.7.1 Marketed 462
7.7.2 Phase III 483
7.7.3 Phase II 498
7.7.4 Phase I 568
7.7.5 Preclinical 616
7.7.6 Suspended 696
7.7.7 Ceased 697
7.8 The Competition Through Close Mechanistic Approximation of Antibody Drugs in Cancer 768
8 Selecting Indication for Antibody Drugs in Oncology 777
8.1 Acute Lymphocytic Leukemia 780
8.2 Acute Myelogenous Leukemia 782
8.3 B-cell Lymphoma 784
8.4 Basal Cell Cancer 786
8.5 Biliary Cancer 787
8.6 Bladder Cancer 788
8.7 Bone Cancer 790
8.8 Brain Cancer 793
8.9 Breast Cancer 795
8.10 Cancer (general) 799
8.11 Carcinoid Tumors 800
8.12 Cervical Cancer 801
8.13 Chronic Lymphocytic Leukemia 803
8.14 Chronic Myelogenous Leukemia 806
8.15 Chronic Myelomonocytic Leukemia 807
8.16 CNS Cancer 808
8.17 Colorectal Cancer 809
8.18 Endometrial Cancer 813
8.19 Esophageal Cancer 814
8.20 Ewing's Sarcoma 815
8.21 Fallopian Tube Cancer 816
8.22 Gastrointestinal Cancer (general) 817
8.23 Gastrointestinal Stomach Cancer 819
8.24 Gastrointestinal Stromal Cancer 821
8.25 Genitourinary Cancer 822
8.26 Glioma 823
8.27 Hairy Cell Leukemia 824
8.28 Head and Neck Cancer 825
8.29 Hematological Cancer (general) 827
8.30 Hodgkin's Lymphoma 828
8.31 Leiomyo Sarcoma 830
8.32 Leukemia (general) 831
8.33 Liver Cancer 833
8.34 Lung Cancer (general) 835
8.35 Lymphoma (general) 837
8.36 Malignant ascites 838
8.37 Melanoma 839
8.38 Merkel Cell Carcinoma 842
8.39 Mesothelioma 843
8.40 Myelodysplastic Syndrome 844
8.41 Myeloma 846
8.42 Nasopharyngeal Cancer 849
8.43 Neuroblastoma 850
8.44 Neuroectodermal Sarcoma 851
8.45 Neuroendocrine Cancer (general) 852
8.46 non-Hodgkin's Lymphoma 853
8.47 Non-Small Cell Lung Cancer 857
8.48 Oesophageal Cancer 860
8.49 Oral Cancer 863
8.50 Osteo Sarcoma 864
8.51 Ovarian Cancer 865
8.52 Pancreatic Cancer 868
8.53 Peritoneal Cancer 871
8.54 Pituitary Adenoma 873
8.55 Prostate Cancer 874
8.56 Renal Cancer 877
8.57 Rhabdomyo Sarcoma 879
8.58 Sarcoma (general) 880
8.59 Skin Appendage Cancer 881
8.60 Skin Cancer (general) 882
8.61 Small Cell Lung Cancer 883
8.62 Soft Tissue Sarcoma 885
8.63 Solid Tumor 886
8.64 Squamous Cell Cancer 890
8.65 Synovial Sarcoma 892
8.66 T-cell Lymphoma 893
8.67 Testicular Cancer 894
8.68 Thymoma Cancer 895
8.69 Thyroid Cancer 896
8.70 Unspecified Cancer Type 898
8.71 Vaccine adjunct 905
8.72 Waldenstrom's hypergammaglobulinemia 906
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator 908
9.1 Changes in the Competitive Landscape: MandA, Bankruptcy and Name Change 913
9.2 Company Facts and Ranking 915
9.3 Competitive Fall-Out Assessment 922
9.4 AandG Pharmaceutical 925
9.5 Abbott 929
9.6 Abcam 938
9.7 Abiogen 946
9.8 Ablynx 955
9.9 AC Immune 960
9.10 Acceleron Pharma 964
9.11 Access 968
9.12 Actinium Pharmaceuticals 974
9.13 Active Biotech 980
9.14 Adherex 984
9.15 Affibody 988
9.16 Affimed Therapeutics 995
9.17 Affitech 1006
9.18 AGY Therapeutics 1013
9.19 Aida Pharmaceuticals 1017
9.20 Alder Biopharmaceuticals 1023
9.21 Alethia Biotherapeutics 1030
9.22 Alexion 1034
9.23 Algeta 1038
9.24 ALSP 1046
9.25 Altor BioScience 1053
9.26 Amgen 1057
9.27 Amorfix Life Sciences 1086
9.28 Antisoma 1091
9.29 Aphios 1097
9.30 Apricus Biosciences 1103
9.31 Arana Therapeutics 1111
9.32 Arca biopharma 1115
9.33 Areva 1119
9.34 arGEN-X 1126
9.35 Astellas 1131
9.36 1AstraZeneca 1135
9.37 AVEO 1156
9.38 Bayer 1167
9.39 Berkeley Lab 1173
9.40 Biocon 1177
9.41 Biogen Idec 1181
9.42 BioInvent 1195
9.43 Biolex 1199
9.44 BioLineRx 1206
9.45 Biosceptre 1210
9.46 Biotecnol 1214
9.47 Biotest 1222
9.48 Boehringer Ingelheim 1226
9.49 Bristol-Myers Squibb 1230
9.50 BTG 1253
9.51 Cancer Innovations 1258
9.52 Cancer Research Technology 1263
9.53 Celldex Therapeutics 1280
9.54 Celltrion 1287
9.55 Celtic Pharma 1297
9.56 Center of Molecular Immunology 1302
9.57 Centrose 1310
9.58 CG Therapeutics 1316
9.59 Circadian Technologies 1320
9.60 CSL 1325
9.61 CuraGen 1329
9.62 CureTech 1333
9.63 Customized Therapeutics 1339
9.64 CytImmune Sciences 1347
9.65 Daiichi Sankyo 1351
9.66 Dendreon 1358
9.67 DiaMedica 1363
9.68 Dompe 1367
9.69 Dr Reddy's 1372
9.70 Dyax 1379
9.71 Eisai 1386
9.72 Elan 1393
9.73 Eli Lilly 1397
9.74 Emergent BioSolutions 1424
9.75 Ergon Pharmaceuticals 1428
9.76 EUSA Pharma 1432
9.77 Expression Drug Designs 1437
9.78 Fabrus 1441
9.79 Faron Pharmaceuticals 1456
9.80 Favrille 1460
9.81 Femta Pharmaceuticals 1467
9.82 FibroGen 1472
9.83 Five Prime Therapeutics 1476
9.84 Fusion Antibodies 1480
9.85 Galaxy Biotech 1484
9.86 GammaCan 1488
9.87 Ganymed Pharmaceuticals 1494
9.88 Gene Techno Science 1498
9.89 Genencor 1502
9.90 Genentech 1507
9.91 Genmab 1517
9.92 Genomic Systems 1538
9.93 GenPat77 1542
9.94 Gilead Sciences 1546
9.95 GlaxoSmithKline 1550
9.96 Gliknik 1558
9.97 Glycotope 1568
9.98 Green Cross 1578
9.99 Hawthorn Pharmaceuticals 1585
9.100 Hoffmann-La Roche 1589
9.101 Human Genome Sciences 1629
9.102 IDM Pharma 1637
9.103 ImClone Systems 1646
9.104 IMED 1653
9.105 Immune Pharmaceuticals 1657
9.106 ImmunoCellular Therapeutics 1661
9.107 ImmunoGen 1665
9.108 Immunomedics 1680
9.109 Immutep 1707
9.110 Innate Pharma 1711
9.111 InNexus Biotechnology 1717
9.112 Intracel 1731
9.113 ISA Pharmaceuticals 1738
9.114 ISU ABXIS 1743
9.115 Johnson and Johnson 1750
9.116 Kaketsuken 1758
9.117 KaloBios 1762
9.118 Kirin Pharma 1766
9.119 Kissei 1773
9.120 Kyowa Hakko Kirin 1780
9.121 Kyto Biopharma 1787
9.122 LFB Biotechnologies 1791
9.123 LG Life Sciences 1805
9.124 MacroGenics 1812
9.125 MAT Biopharma 1820
9.126 Medarex 1827
9.127 MediGene 1834
9.128 MedImmune 1841
9.129 Menarini 1846
9.130 Merck and Co 1851
9.131 Merck KGaA 1857
9.132 Merrimack 1870
9.133 Micromet 1876
9.134 Mitsubishi Tanabe Pharma 1881
9.135 Mycenax 1885
9.136 Neovacs 1889
9.137 Neuren 1895
9.138 NIH 1899
9.139 NKT Therapeutics 1905
9.140 Non-industrial Sources 1909
9.141 Northwest Biotherapeutics 1917
9.142 Novartis 1922
9.143 OncoMed 1936
9.144 OncoTherapy Science 1942
9.145 Oncothyreon 1946
9.146 Onyvax 1951
9.147 Oxford BioMedica 1956
9.148 Paladin Labs 1961
9.149 Panacea 1968
9.150 PanGenetics 1974
9.151 Patrys 1979
9.152 Pepscan Therapeutics 1986
9.153 Peregrine Pharmaceuticals 1991
9.154 Perseus Proteomics 1998
9.155 Pfizer 2003
9.156 PharmAbcine 2022
9.157 Philogen 2045
9.158 Pierre Fabre 2051
9.159 Prima Biomed 2060
9.160 PROBIOMED 2065
9.161 ProCell Therapeutics 2072
9.162 Prochon Biotech 2076
9.163 Progenics Pharmaceuticals 2082
9.164 Ramot 2087
9.165 Recepta biopharma 2091
9.166 Receptor BioLogix 2095
9.167 Regeneron 2101
9.168 Sanofi 2110
9.169 SBI Biotech 2116
9.170 Scancell 2121
9.171 Seattle Genetics 2125
9.172 Shanghai CP Guojian 2136
9.173 Shenogen 2146
9.174 Stainwei Biotech 2150
9.175 Sunol Molecular 2156
9.176 SuppreMol 2161
9.177 Switch Pharma 2166
9.178 Symphogen 2170
9.179 Synageva BioPharma 2178
9.180 SynerGene Therapeutics 2188
9.181 Tactic Pharma 2192
9.182 Takeda 2196
9.183 Tamir Biotechnology 2202
9.184 Targa Therapeutics 2207
9.185 TeGenero 2215
9.186 Teva 2219
9.187 ThromboGenics 2226
9.188 Titan Pharmaceuticals 2231
9.189 Tolerx 2237
9.190 Tracon Pharmaceuticals 2242
9.191 Transgene 2247
9.192 Trillium Therapeutics 2252
9.193 Trion Pharma 2256
9.194 UCB 2264
9.195 United Therapeutics 2270
9.196 Vaccinex 2274
9.197 VasGene Therapeutics 2283
9.198 Viragen 2287
9.199 Viventia Biotech 2293
9.200 Wakunaga 2297
9.201 Wilex 2303
9.202 XBiotech 2307
9.203 Xencor 2312
9.204 Xerion 2331
9.205 Xoma 2337
9.206 Y's Therapeutics 2343
9.207 YM BioSciences 2347
9.208 Zenotech 2354
10 Disclaimer 2361

1.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Antibody Drugs in Cancer 371
Figure 2: The Drug-Target Competitive Landscape of Antibody Drugs in Cancer - Large Cluster 376
Figure 3: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 1(2) 377
Figure 4: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 2(2) 378
Figure 5: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 1 (2) 379
Figure 6: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 2 (2) 380
Figure 7: Number of Companies per Ranking Level 917

1.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Antibody Drug Pipeline in Oncology by Stage of Development 35
Table 3: Head to Head Target Competition among Antibody Drugs 35
Table 4: Overview of Drug Target Strategy Themes 40
Table 5: Ceased Targets of Antibody Drugs in Cancer 41
Table 6: Official Gene Symbol to Target Profle 43
Table 7: Mutation Frequencies of Antibody Drug Targets 357
Table 8: Identity of Drug Targets with Available Biological Structures 364
Table 9: Number of Target-Target Interactions among Targets of Antibody Drugs in Cancer 369
Table 10: Available Protein Expression Profiles of Antibody Drug Targets 372
Table 11: Pathway Summary 383
Table 12: Drug Targets without any Identified Assigned Pathways 383
Table 13: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology 386
Table 14: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology 400
Table 15: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology 418
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 423
Table 17: Top Competitive Target Strategies of Antibody Drugs in Cancer 424
Table 18: New and Unique Target Strategies of Antibody Drugs in Cancer in Pre-registration or on the Marketed 426
Table 19: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Cancer Being Marketed 427
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Antibody Drugs in Cancer 428
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Cancer 429
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Antibody Drugs in Cancer 430
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Cancer 433
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Antibody Drugs in Cancer 435
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Cancer 439
Table 26: New and Unique Target Strategies in Preclinical Development of Antibody Drugs in Cancer 442
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Cancer 447
Table 28: Target Strategies of Suspended or Terminated Antibody Drugs in Cancer 451
Table 29: Connecting Target Strategy with Its Profile Identification Number 456
Table 30: The Competition Through Close Mechanistic Approximation Among Antibody Drugs in Cancer 768
Table 31 Competitive Summary by Cancer Indication of Antibody Drugs 778
Table 32: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia 780
Table 33: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 781
Table 34: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia 782
Table 35: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 783
Table 36: Target Strategy Development Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma 784
Table 37: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 785
Table 38: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer 786
Table 39: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Biliary Cancer 787
Table 40: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs 787
Table 41: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bladder Cancer 788
Table 42: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 788
Table 43: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bone Cancer 790
Table 44: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs 792
Table 45: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Brain Cancer 793
Table 46: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 794
Table 47: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Breast Cancer 795
Table 48: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 797
Table 49: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer (general) 799
Table 50: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Carcinoid Tumors 800
Table 51: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cervical Cancer 801
Table 52: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 801
Table 53: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia 803
Table 54: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 804
Table 55: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia 806
Table 56: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 806
Table 57: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelomonocytic Leukemia 807
Table 58: Target Strategy Development Profiles of Antibody Drugs for the Treatment of CNS Cancer 808
Table 59: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Colorectal Cancer 809
Table 60: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 811
Table 61: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Endometrial Cancer 813
Table 62: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Esophageal Cancer 814
Table 63: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ewing's Sarcoma 815
Table 64 The Competition through Close Mechanistic Approximation between Ewing’s Sarcoma Drugs 815
Table 65: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer 816
Table 66: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general) 817
Table 67: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 818
Table 68: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer 819
Table 69: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 820
Table 70: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer 821
Table 71: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer 822
Table 72: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs 822
Table 73: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Glioma 823
Table 74: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia 824
Table 75: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs 824
Table 76: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer 825
Table 77: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 826
Table 78: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general) 827
Table 79: The Competition through Close Mechanistic Approximation between Hematological Cancer Drugs 827
Table 80: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hodgkin's Lymphoma 828
Table 81: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs 829
Table 82: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma 830
Table 83: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leukemia (general) 831
Table 84: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs 832
Table 85: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Liver Cancer 833
Table 86: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 834
Table 87: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lung Cancer (general) 835
Table 88: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 836
Table 89: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lymphoma (general) 837
Table 90: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Malignant ascites 838
Table 91: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Melanoma 839
Table 92: The Competition through Close Mechanistic Approximation between Melanoma Drugs 840
Table 93: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma 842
Table 94: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Mesothelioma 843
Table 95: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome 844
Table 96: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 844
Table 97: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myeloma 846
Table 98: The Competition through Close Mechanistic Approximation between Myeloma Drugs 847
Table 99: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer 849
Table 100: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroblastoma 850
Table 101: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma 851
Table 102: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general) 852
Table 103: Target Strategy Development Profiles of Antibody Drugs for the Treatment of non-Hodgkin's Lymphoma 853
Table 104: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 855
Table 105: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer 857
Table 106: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 859
Table 107: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer 860
Table 108: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 862
Table 109: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oral Cancer 863
Table 110: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma 864
Table 111: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 864
Table 112: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ovarian Cancer 865
Table 113: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 867
Table 114: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer 868
Table 115: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 870
Table 116: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer 871
Table 117: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 872
Table 118: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pituitary Adenoma 873
Table 119: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Prostate Cancer 874
Table 120: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 876
Table 121: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Renal Cancer 877
Table 122: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 878
Table 123: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma 879
Table 124: The Competition through Close Mechanistic Approximation between Rhabdomyo Sarcoma Drugs 879
Table 125: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Sarcoma (general) 880
Table 126: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Appendage Cancer 881
Table 127: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Cancer (general) 882
Table 128: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer 883
Table 129: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 884
Table 130: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma 885
Table 131: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Solid Tumor 886
Table 132: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 888
Table 133: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer 890
Table 134: The Competition through Close Mechanistic Approximation between Squamous Cell Cancer Drugs 890
Table 135: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma 892
Table 136: Target Strategy Development Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma 893
Table 137: The Competition through Close Mechanistic Approximation between T-cell Lymphoma Drugs 893
Table 138: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Testicular Cancer 894
Table 139: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thymoma Cancer 895
Table 140: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thyroid Cancer 896
Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 896
Table 142: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Type 898
Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Type Drugs 902
Table 144: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Vaccine adjunct 905
Table 145: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia 906
Table 146: The Competition through Close Mechanistic Approximation between of Waldenstrom's hypergammaglobulinemia Drugs 906
Table 147: Competitive Summary by Investigator of Antibody Drug Development in Cancer 908
Table 148: Summary Table of Corporate Changes in the Competitive Landscape of Cacner Antibody Drug Development 913
Table 149: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 916
Table 150: Example of a Competitive Fall-Out Table (Targeting TNFSF11 Modified) 922
Table 151: AandG Pharmaceutical's Included Antibody Drugs in Oncology and Competitive Fall-Out 926
Table 152: Abbott's Included Antibody Drugs in Oncology and Competitive Fall-Out 931
Table 153: Abcam's Included Antibody Drugs in Oncology and Competitive Fall-Out 941
Table 154: Abiogen's Included Antibody Drugs in Oncology and Competitive Fall-Out 949
Table 155: Ablynx's Included Antibody Drugs in Oncology and Competitive Fall-Out 957
Table 156: AC Immune's Included Antibody Drugs in Oncology and Competitive Fall-Out 961
Table 157: Acceleron Pharma's Included Antibody Drugs in Oncology and Competitive Fall-Out 965
Table 158: Access’ Included Antibody Drugs in Oncology and Competitive Fall-Out 970
Table 159: Actinium Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 976
Table 160: Active Biotech's Included Antibody Drugs in Oncology and Competitive Fall-Out 981
Table 161: Adherex's Included Antibody Drugs in Oncology and Competitive Fall-Out 985
Table 162: Affibody's Included Antibody Drugs in Oncology and Competitive Fall-Out 991
Table 163: Affimed Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 999
Table 164: Affitech's Included Antibody Drugs in Oncology and Competitive Fall-Out 1008
Table 165: AGY Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1014
Table 166: Aida Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1019
Table 167: Alder Biopharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1025
Table 168: Alethia Biotherapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1031
Table 169: Alexion's Included Antibody Drugs in Oncology and Competitive Fall-Out 1035
Table 170: Algeta's Included Antibody Drugs in Oncology and Competitive Fall-Out 1041
Table 171: ALSP's Included Antibody Drugs in Oncology and Competitive Fall-Out 1049
Table 172: Altor BioScience's Included Antibody Drugs in Oncology and Competitive Fall-Out 1054
Table 173: Amgen's Included Antibody Drugs in Oncology and Competitive Fall-Out 1063
Table 174: Amorfix Life Sciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1088
Table 175: Antisoma's Included Antibody Drugs in Oncology and Competitive Fall-Out 1093
Table 176: Aphios’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1099
Table 177: Apricus Biosciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1106
Table 178: Arana Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1112
Table 179: Arca biopharma's Included Antibody Drugs in Oncology and Competitive Fall-Out 1116
Table 180: Areva's Included Antibody Drugs in Oncology and Competitive Fall-Out 1122
Table 181: arGEN-X's Included Antibody Drugs in Oncology and Competitive Fall-Out 1128
Table 182: Astellas’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1132
Table 183: AstraZe

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Drug Discovery and Development in United States: Omeros Corporation – Product Pipeline Review – H2 2011

Drug Discovery and Development in United States: Omeros Corporation – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ...

Pharmaceutical in Japan: Astellas Pharma Inc. – Product Pipeline Review – H2 2011

Pharmaceutical in Japan: Astellas Pharma Inc. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the Astellas Pharma Inc.’s research and development focus. The report includes data on current developmental pipeline, complete ...

Pathology in United States: Boehringer Ingelheim GmbH – Product Pipeline Review – H2 2011

Pathology in United States: Boehringer Ingelheim GmbH – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ...


10 Companies

Company Profiles


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.